Abstract:Flanagan Balawajder and colleagues 1 conducted a cross-sectional national survey of 1028 jails from June 2022 through April 2023 to assess the availability of substance use disorder (SUD) treatment and, more specifically, medications for treatment of opioid use disorder (MOUD). In addition to the large sample size, another strength of this study was that county-level data were incorporated in analyses to better understand communities in which jails were located. Data included opioid overdoses, MOUD availability, urbanicity, and the key 16 socioeconomic factors used by the Centers for Disease Control and Prevention 2020 Social Vulnerability Index summary, such as poverty level, housing, and transportation. While results of this analysis identified that 70% of jails offered any form of SUD treatment, 44% of jails offered some form of MOUD and only 13% of jails offered at least 1 of the 3 Food and Drug Administration (FDA)–approved forms of MOUD to anyone specifically with a known diagnosis of an OUD. Additional county-level data analyses demonstrated that jails that did not offer contracted or direct health care services had 50% to 80% lower odds of offering SUD treatment or MOUD and counties that had higher Social Vulnerability Index scores had a 70% decrease in the odds of offering any SUD treatment and a 65% decrease in the odds of offering MOUD to anyone with an OUD diagnosis. These study findings have significant implications due to the large population of incarcerated individuals in the US with SUDs. As of March 14, 2024, 1 in 5 of the more than 700 000 persons in US jails were incarcerated for drug-related offenses (361 000 individuals on any given day). 2 Furthermore, persons in jail are almost 13 times more likely to have a specific treatable Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition ( DSM-5 ) SUD compared with people in the general population. 3 Additionally, there is substantial evidence that all 3 forms of FDA-approved medications for the treatment of DSM-5 moderate to severe OUD (buprenorphine, methadone, and extended-release naltrexone) are associated with reduced opioid craving, opioid use, overdose, and death, with buprenorphine and methadone being the most effective 4 ; however, only 13% of jails provided MOUD to individuals with known OUDs in this study. 1 It is well known that the lack of MOUD while in jail is associated with increased risk of death during incarceration. The number of people who died of intoxication or withdrawal while under jail supervision between 2000 and 2018 in the US increased by almost 400%, with most of these individuals dying within just 1 day of admission. 2 The Bureau of Justice Assistance, National Institute of Corrections, and American Society of Addiction Medicine have recommended that individuals with OUD who are at risk for opioid withdrawal be offered initiation and continuation of long-term MOUD in all US jails. 5 Reentry to the community after release from jail is also a critical time to intervene. There were more than 80 000 fatal opioid overdoses predominantly due to illicitly manufactured fentanyl in US communities in 2023 alone. Persons released from jail are more likely to die from overdose typically in the first 2 weeks after they reenter the community due to reduced tolerance during lack of treatment while incarcerated. 6 Thus, initiating MOUD while persons are in jail and continuing into the community is absolutely critical to save lives. 5 Methadone and buprenorphine have been shown to reduce overdose deaths by 80% in the first month after an individual is released to the community. 7 Furthermore, MOUD has other benefits through reducing HIV and hepatitis C virus acquisition and improving HIV viral suppression and hepatitis C virus cure. Providing health care in jail facilities and understanding community-level treatment availability are essential to providing MOUD and linking individuals to clinicians who can continue MOUD in the community. As shown in this study, jails that did not offer health care services were markedly less likely to offer SUD treatment or MOUD specifically. If clinicians with MOUD expertise are not available in jail facilities, telehealth with outside clinicians could be used. To improve linkage in the community, a concerted effort is needed to identify clinicians who will accept patients and can provide the form of MOUD that an individual chooses. There is a known lack of clinicians who can prescribe all 3 forms of MOUD in many communities, which thus negatively impacts the ability for persons to retain on treatment in the community. Individual-level needs that may be associated with access to and retention on MOUD in the reentry period prior to release must also be assessed in jails. As identified in this study, inadequate transpo -Abstract Truncated-

Evidence for X/X chromosome translocation in humans

"They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder

Opioid Maintenance Therapy: A Review of Methadone, Buprenorphine, and Naltrexone Treatments for Opioid Use Disorder

Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date

Federal opioid agonist therapy policy: interrupted time series analysis of the impact of the methadone exemption removal across eight provinces in Canada

Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder

Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada

IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders

Opioid use disorder: current trends and potential treatments

Management of Critically Ill Patients Receiving Medications for Opioid Use Disorder

Improving methadone access for rural communities in the USA: lessons learned from COVID-19 adaptations and international models of care

Recent modifications to the US methadone treatment system are a Band-Aid-not a solution-to the nation's broken opioid use disorder treatment system

Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails

Navigating new norms: Addiction specialists' perspectives on opioid use disorder treatments and policy challenges in the fentanyl era

A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder

Methadone's Resurgence in Bridging the Treatment Gap in the Overdose Crisis: Position Statement of AMERSA, Inc (Association for Multidisciplinary Education, Research, Substance Use, and Addiction)

The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review

An international comparative policy analysis of opioid use disorder treatment in primary care across nine high-income jurisdictions

Characterising methamphetamine/amphetamine use among opioid agonist therapy‐seeking adults with prescription‐type opioid use disorder in Canada

Medications for Opioid Use Disorder in Rural United States: A Critical Review of the Literature, 2004–2021